Interestingly, mutations in RET protein have been previously considered as a hallmark of medullary thyroid carcinoma, since they were reported in 40–80% of medullary thyroid cancer patients and were highly associated with poor prognosis—in terms of more metastasis, larger tumor sizes and poorer overall survival8,34–36. Here, RET is linked to medullary thyroid gland carcinoma.